Containing Heterocyclic Ring Patents (Class 435/53)
  • Patent number: 5215894
    Abstract: The present invention is concerned with a novel biotransformation process for producing 17.beta.-N-monosubstituted carbamoyl-11-oxo-4-aza-5-.alpha.-androst-3-ones of the formula: ##STR1## These compounds are testosterone 5-.alpha. reductase inhibitors and are produced via a claimed novel biotransformation process using the green algae, Selenastrum capricornutum.
    Type: Grant
    Filed: February 25, 1992
    Date of Patent: June 1, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Byron H. Arison, Josephine R. Carlin, Edamanal S. Venkataramani
  • Patent number: 5204253
    Abstract: A process is described which uses a "cold" gas shock to accelerate microprojectiles wherein particles are presented to the gas shock on a planar surface perpendicular to the plane of expansion of the gas shock wave. Several different apparatus capable of accomplishing this method are described.
    Type: Grant
    Filed: May 29, 1990
    Date of Patent: April 20, 1993
    Assignee: E. I. Du Pont de Nemours and Company
    Inventors: John C. Sanford, Michael J. DeVit, Ronald F. Bruner, Stephen A. Johnston
  • Patent number: 5084388
    Abstract: A method of producing a brassinosteroid is disclosed, wherein crown gall cells capable of producing the brassinosteroid are cultured in a culture medium in the presence of a cultivation aid selected from auxins, sterols, squalene, casamino acid and mixtures thereof.
    Type: Grant
    Filed: December 18, 1990
    Date of Patent: January 28, 1992
    Assignees: Somar Corporation and The Institute of Physical and Chemical Research, The Institute of Physical and Chemical Research
    Inventors: Hiroshi Saimoto, Masako Otsuka, Mifumi Yamamoto, Masao Kawashima, Shozo Fujioka, Akira Sakurai, Takao Yokota, Kunihiko Shono
  • Patent number: 4990448
    Abstract: A new antibiotic designated BU-4061T is produced by fermentation of actinomycete strain Q996-17 (ATCC-53904). The BU-4061T antibiotic exhibits both in vitro and in vivo antitumor activity.
    Type: Grant
    Filed: August 4, 1989
    Date of Patent: February 5, 1991
    Assignee: Bristol-Myers Company
    Inventors: Masataka Konishi, Minoru Hanada, Yuji Nishiyama
  • Patent number: 4814324
    Abstract: The compounds of Formula I are produced by the aerobic fermentation of a fungus of the genus GLIOCLADIUM, ATCC No. 20826. ##STR1## The compounds of Formula I are inhibitors of testosterone 5.alpha.-reductase and are useful in the treatment and prevention of acne, seborrhea, female hirsutism and benign prostatic hypertrophy.
    Type: Grant
    Filed: March 6, 1987
    Date of Patent: March 21, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Robert P. Borris, Richard W. Burg, Otto D. Hensens, Leeyuan Huang, Livia Kelemen, Sagrario Mochales
  • Patent number: 4592868
    Abstract: There is provided the novel compound 11-hydroxypregn-4-en-3-one-20-carbaldehyde, as well as a microbial method for production of the same. This novel compound is of value as a starting material for antiinflammatory corticoids such as hydrocortisone, cortisone, prednisolone and prednisone.
    Type: Grant
    Filed: May 7, 1984
    Date of Patent: June 3, 1986
    Assignee: Kuraray Co., Ltd.
    Inventors: Masao Tsuji, Fumio Mori, Yoshihiro Ichihara
  • Patent number: 4545991
    Abstract: Difficidin and derivative antibacterial compounds of the formula: ##STR1## where R.sub.a and R.sub.b are members independently selected from the group consisting of hydrogen; alkali metal and alkaline earth metal cations; ammonium; and substituted ammonium; and R.sup.1 is hydrogen or hydroxy.
    Type: Grant
    Filed: June 13, 1983
    Date of Patent: October 8, 1985
    Assignee: Merck & Co., Inc.
    Inventors: Sheldon B. Zimmerman, Kenneth E. Wilson, Richard L. Monaghan, Sagrario M. Del Val, Maria I. M. Fernandez, Otto D. Hensens, James E. Flor, Cheryl Deriso
  • Patent number: 4528271
    Abstract: Microbiological conversions of cyclodextrins are intensified by adding to the reaction mixture 0.2 to 3 moles of .alpha.-, .beta.- or .gamma.-cyclodextrin or an optical mixture thereof pro mole of the steroid substrate, before, at the beginning or during the conversion. The cyclodextrin if desired, can be removed after the reaction. In this way the reaction velocity can be increased, the reaction time is reduced, the substrate concentration in the solution, i.e. its solubility is increased or the so called product inhibition may be avoided. In certain cases of more alternatives the desired reaction can be catalyzed and in this manner the selectivity is increased.
    Type: Grant
    Filed: September 24, 1982
    Date of Patent: July 9, 1985
    Assignees: Richter Gedeon Vegyeszeti Gyar Rt., Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt.
    Inventors: Eva Udvardy Nagy nee Cserey Pechany, Istvan Bartho, Gabor Hantos, Maria Trinn, Zsuzsa Vida, Jozsef Szejtli, Agnes Stadler nee Szoke, Ilona Habon, Marta Balazs nee Czurda